Oncology最新文献

{"title":"Efficacy of Locoregional Treatment for Oligo-Drug-Resistant Lesions during First-Line Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma: A Single-Center Retrospective Study.","authors":"Tasuku Nakabori, Sena Higashi, Kaori Mukai, Toshiki Ikawa, Noboru Maeda, Masaki Kawabata, Kana Hosokawa, Kazuhiro Kozumi, Makiko Urabe, Yugo Kai, Ryoji Takada, Kenji Ikezawa, Koji Konishi, Katsuyuki Nakanishi, Kazuyoshi Ohkawa","doi":"10.1159/000546211","DOIUrl":"10.1159/000546211","url":null,"abstract":"<p><strong>Introduction: </strong>Despite recent advancements, outcomes for unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo/bev) remain suboptimal, with drug resistance posing a major challenge. This study evaluated the efficacy of additional locoregional treatments (LRTs) for oligo-atezo/bev-resistant lesions.</p><p><strong>Methods: </strong>We retrospectively analyzed patients with intermediate-stage and advanced-stage HCC who developed drug-resistant lesions during first-line atezo/bev therapy. Patients were divided into two groups: the combination therapy group (n = 10) receiving additional LRT and the atezo/bev alone group (n = 26). Progression-free survival (PFS) 1 was measured from atezo/bev therapy initiation to progressive disease (PD) or death, whereas PFS2 was calculated from atezo/bev therapy initiation to PD of second-line therapy or death. The PFS1 in the combination therapy group was compared to the PFS1 and PFS2 in the atezo/bev alone group. Two analyses were performed for the PFS and overall survival (OS): one including the total cohort and the other restricted to those eligible for LRT upon the appearance of atezo/bev-resistant lesions. Changes in the hepatic reserve before and after LRT were also assessed.</p><p><strong>Results: </strong>LRT, followed by continued atezo/bev therapy, safely eradicated drug-resistant lesions in the combination therapy group, without compromising the hepatic reserve. All patients in the combination therapy group transitioned to second-line treatment due to preserved hepatic reserve after PD. The PFS1 in the combination therapy group was longer than the PFS1 and PFS2 in the atezo/bev alone group in both the total cohort and LRT-eligible subgroup. Similarly, the OS in the combination therapy group was longer than in the atezo/bev alone group in both analyses.</p><p><strong>Conclusion: </strong>LRTs may provide a viable option for managing oligo-drug-resistant lesions during first-line atezo/bev therapy for unresectable HCC when safely administered.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"227-239"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Study on the Improvement of Quality of Survival in Cervical Cancer Patients after Chemoradiotherapy through an Integrated Traditional Chinese and Western Medicine Therapy Based on a Syndrome Differentiation-Driven Dynamic Intervention Strategy.","authors":"Shuangshuang Wang, Chang She, Guo Xu, Xiaolin Hu, Weina Yan","doi":"10.1159/000548661","DOIUrl":"10.1159/000548661","url":null,"abstract":"<p><strong>Introduction: </strong>Cervical cancer patients frequently experience impaired quality of life (QoL) and treatment-related toxicities following chemoradiotherapy. This study assessed whether a dynamic integrated Chinese and Western medicine (CWM) intervention, guided by traditional Chinese medicine (TCM) syndrome differentiation, improves QoL and outcomes in these patients.</p><p><strong>Methods: </strong>A total of 176 post-chemoradiotherapy cervical cancer patients were randomized to a control group (conventional Western care) or an intervention group (conventional care + dynamic TCM intervention). QoL (EORTC QLQ-C30), psychological resilience (CD-RISC), immune function (CD4+, CD8+, CD4+/CD8+ ratio), cancer-related fatigue, myelosuppression, gastrointestinal symptoms, and radiation enteritis incidence were evaluated pre-and post-intervention. Multivariable Cox proportional hazards regression analysis was used to analyze the independent impact of the integrated Chinese-Western medicine dynamic intervention on the overall survival (OS) of cervical cancer patients after chemoradiotherapy. The 5-year OS rate was analyzed using Kaplan-Meier.</p><p><strong>Results: </strong>Post-intervention, the intervention group showed significantly better QLQ-C30 and CD-RISC scores than controls (p < 0.05). Survival analysis revealed a higher 5-year OS rate in the intervention group (73.10% vs. 52.74%; p = 0.0179). Multivariable Cox proportional hazards regression analysis showed that after adjusting for confounding factors such as age, clinical stage, pathological type, treatment type, and TCM syndrome type, the intervention group significantly reduced the risk of death in cervical cancer patients after chemoradiotherapy compared to the control group (HR = 0.523, 95% CI: 0.291-0.942, p = 0.028). Immune function improved significantly in the intervention group (higher CD4+, CD4+/CD8+ ratio; lower CD8+; p < 0.05). While acute gastrointestinal symptom relief and acute radiation enteritis incidence showed no significant difference, the intervention group demonstrated significantly lower fatigue, reduced myelosuppression severity, fewer delayed gastrointestinal symptoms, and lower chronic radiation enteritis incidence (p < 0.05).</p><p><strong>Conclusion: </strong>The dynamic integrated CWM approach, through stage-specific precise intervention based on syndrome differentiation, synergistically improves QoL and survival while reducing specific toxicities in cervical cancer patients post-chemoradiotherapy.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"793-807"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145677680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer with Primary Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Cohort Study.","authors":"Yonghong Li, Yirui Liu, Yi Peng, Jing Tang, Xiaobing Li","doi":"10.1159/000546834","DOIUrl":"10.1159/000546834","url":null,"abstract":"<p><strong>Introduction: </strong>In this study, we aimed to evaluate the efficacy and safety of the combination therapy with chemotherapy and anlotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations who exhibit primary resistant to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).</p><p><strong>Methods: </strong>Clinical data were collected from patients with advanced NSCLC harboring EGFR mutations and exhibiting primary resistance to EGFR-TKI, who were treated with a combination of chemotherapy and anlotinib. The primary endpoints were overall response rate (ORR), progression-free survival (PFS), disease control rate, overall survival (OS), and treatment-related adverse events (AEs).</p><p><strong>Results: </strong>A total of 34 patients with advanced NSCLC harboring EGFR mutations and exhibiting primary resistance to EGFR-TKI were enrolled. The ORR and DCR for the treatment with chemotherapy plus anlotinib were 32.35% and 64.71%, respectively. The median PFS and OS were 5 months and 9 months, respectively. Compared to patients with EGFR exon 19 deletion mutations, those with EGFR exon 21 L858R mutations derived greater benefit from the treatment (mPFS = 4.0 months vs. 5.0 months, p < 0.05; mOS = 9.0 months vs. 10.0 months, p < 0.05). The common AEs were myelosuppression, hypertension, proteinuria, and hand-foot syndrome. Most AEs were mild and well tolerated. These findings suggest that chemotherapy combined with anlotinib may be a promising strategy to overcome primary resistance to EGFR-TKIs in patients with advanced NSCLC.</p><p><strong>Conclusion: </strong>The combination of chemotherapy and anlotinib appears to be an effective and well-tolerated treatment strategy in patients with advanced NSCLC exhibiting primary resistance to EGFR-TKIs. Further studies are warranted to validate these findings and investigate long-term clinical outcomes.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"433-439"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDG-PET/CT and CT Compared for Evaluation of Tumor Response to First-Line Immunotherapy and Prediction of Prognosis in Non-Small-Cell Lung Cancer Patients.","authors":"Kazuhiro Kitajima, Kosuke Matsuda, Toshiyuki Minami, Akifumi Nakamura, Kozo Kuribayashi, Soichiro Funaki, Takashi Kijima, Koichiro Yamakado","doi":"10.1159/000546339","DOIUrl":"10.1159/000546339","url":null,"abstract":"<p><strong>Introduction: </strong>Immunotherapy-modified Positron Emission Tomography Response Criteria in Solid Tumors (imPERCIST) using FDG-PET/CT and immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) using CT were compared for evaluation of response, prognosis prediction, and effect on patient management in non-small-cell lung cancer (NSCLC) patients treated with first-line immunotherapy, or immunotherapy and chemotherapy combined.</p><p><strong>Methods: </strong>Thirty-three patients (26 males, median 68.0 years old) with histologically NSCLC without EGFR/ALK/KRAS alterations underwent pembrolizumab treatment only or immunotherapy combined with chemotherapy. FDG-PET/CT and diagnostic CT scanning was performed at the baseline and after two to four cycles (2 in 8, 3 in 12, 4 in 13 patients). Findings for therapeutic response obtained with imPERCIST and irRECIST were compared. Progression-free survival (PFS) and overall survival (OS) were examined using log-rank and Cox methods.</p><p><strong>Results: </strong>imPERCIST indicated that 10 patients had complete metabolic response (CMR), eight partial metabolic response (PMR), three stable metabolic disease (SMD), and 12 progressive metabolic disease (PMD), while irRECIST showed that two had complete response (CR), 14 PR, nine SD, and eight PD, indicating substantial concordance (κ = 0.615). Twenty-eight patients showed progression and 18 died from NSCLC after a median 16.2 months. Patients showing response based on imPERCIST and irRECIST (CMR/PMR, CR/PR, respectively) showed significantly longer PFS and OS than nonresponders (SMD/PMD, SD/PD, respectively) (imPERCIST: p < 0.0001 and p = 0.0001, respectively; irRECIST: p = 0.0018 and p = 0.011, respectively). imPERCIST resulted in a change of management in 12 of the 33 patients (36.3%) with an additional effect on patient management in 4 patients (12.1%) evaluated by irRECIST.</p><p><strong>Conclusion: </strong>For evaluation of NSCLC patients for tumor response and patient management following first-line immunotherapy or that combined with chemotherapy, and predicting prognosis, both FDG-PET/CT and CT findings are accurate, with FDG-PET/CT being superior.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"355-367"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular Carcinoma.","authors":"Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Hidenori Toyoda, Yuichi Koshiyama, Chikara Ogawa, Hiroki Nishikawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Hidenao Noritake, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Kosuke Matsui, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hironori Tanaka, Tomoko Aoki, Hideyuki Tamai, Fujimasa Tada, Yuki Kanayama, Kazunari Tanaka, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Teruki Miyake, Osamu Yoshida, Michitaka Imai, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Masatoshi Kudo, Yoichi Hiasa, Takashi Kumada","doi":"10.1159/000547353","DOIUrl":"10.1159/000547353","url":null,"abstract":"<p><strong>Aims: </strong>Sustained virological response (SVR) is a favorable prognostic factor for patients with hepatocellular carcinoma (HCC) caused by hepatitis C virus (HCV) treated curatively. This study aimed to evaluate the impact of SVR on atezolizumab plus bevacizumab (Atez/Bev) therapy for unresectable HCC (uHCC) caused by HCV.</p><p><strong>Methods: </strong>A retrospective analysis of 364 uHCC patients treated with Atez/Bev (September 2020-April 2025) and divided into SVR (n = 284) and non-SVR (n = 80) groups was performed, with clinical characteristics, prognosis, and adverse events compared.</p><p><strong>Results: </strong>There were no significant differences between the groups for age, sex, platelet count, AFP, or BCLC stage. However, the SVR group showed a significantly better ALBI score (-2.50 vs. -2.16) and lower AST (33 vs. 57 IU/L) and ALT (23 vs. 40 IU/L) levels (p < 0.01). Median progression-free survival (PFS) was 7.1 months in the SVR group and 6.1 months in the non-SVR group (p = 0.443), and median overall survival (OS) was 20.9 months in the SVR group and 18.9 months in the non-SVR group, with no significant differences between the groups (p = 0.560). Following IPW adjustment for factors related to OS, there was no significant difference regarding PFS (p = 0.921) and OS (p = 0.927). Multivariate analysis identified age ≥75 years and poor hepatic function (mALBI grade 2b/3) as independent predictors of poor OS; SVR status was not an independent factor. Changes in ALBI and Child-Pugh scores over time were not significantly different between the groups. In the non-SVR group, adverse events were more common as compared to the SVR group, including liver dysfunction (27.5% vs. 13.0%, p < 0.001) and edema/ascites (12.5% vs. 9.2%, p = 0.015).</p><p><strong>Conclusions: </strong>Although SVR was not independently associated with better survival, patients with SVR had preserved liver function and experienced fewer adverse events. These factors may indirectly support improved tolerability and therapeutic options during Atez/Bev therapy for HCV-related uHCC.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"487-496"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Hepsin Expression Associates with a Better Response to Gemcitabine-Based Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.","authors":"Sini Vahtera, Jaana Hagström, Harri Mustonen, Topi Aulis Tervonen, Juha Klefström, Malin Sund, Caj Haglund, Hanna Seppänen","doi":"10.1159/000547820","DOIUrl":"10.1159/000547820","url":null,"abstract":"<p><strong>Introduction: </strong>Hepsin is a type 2 transmembrane serine protease, primarily located on the cell membrane, which can degrade the extracellular matrix and modify connections between cells and the extracellular matrix. Given these features, hepsin is thought to play a role in cancer invasion and metastasis. While studied in various other cancers, hepsin's role in pancreatic cancer remains unexamined.</p><p><strong>Methods: </strong>Our study included 223 patients diagnosed with pancreatic ductal adenocarcinoma. Among these, 66 received neoadjuvant therapy and these were analyzed separately. Tissue microarrays and immunohistochemistry were used to assess the expression of hepsin in pancreatic ductal adenocarcinoma tissue. Hepsin expression intensity, ranging from negative to strong, was evaluated against clinicopathological parameters, including age at surgery, sex, T-stage, N-stage, tumor grade, perivascular and perineural invasion, CA19-9 levels, ASA class, stage, and, in the neoadjuvant-treated group, response to neoadjuvant therapy.</p><p><strong>Results: </strong>A strong hepsin expression was observed in 105 (67%) patients who did not receive neoadjuvant therapy, while 27 (42%) neoadjuvant-treated patients exhibited a strong expression. Hepsin expression did not associate with survival in either group. In the neoadjuvant-treated group, a strong positivity was, however, associated with a lower T-stage (p = 0.005) and higher N-stage (p = 0.048). Among those receiving gemcitabine-based chemotherapy, a weaker hepsin expression was associated with a better treatment response (p = 0.011).</p><p><strong>Conclusions: </strong>A low hepsin expression following neoadjuvant therapy is associated with a better treatment response among those receiving gemcitabine-based treatment. Thus, hepsin does not appear to influence prognosis in pancreatic cancer patients, regardless of whether they received neoadjuvant therapy or not.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"592-600"},"PeriodicalIF":1.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Hypoglycemic Agents with the Risk of Platinum-Based Chemotherapy-Induced Peripheral Neuropathy in Patients with Type 2 Diabetes Mellitus.","authors":"Takeshi Horii, Kenji Onda, Airi Yutasaka, Masaya Hasumi, Saori Yoda, Kenichi Suzuki, Kiyoshi Mihara","doi":"10.1159/000549964","DOIUrl":"10.1159/000549964","url":null,"abstract":"<p><strong>Introduction: </strong>In patients with cancer who also have type 2 diabetes (T2D), platinum-based chemotherapy can worsen the neuropathy owing to its neurotoxicity. Glucose-lowering agents may mitigate chemotherapy-induced peripheral neuropathy by improving glycemic control and reducing metabolic stress. However, their clinical utility in reducing the risk of chemotherapy-induced peripheral neuropathy-potentially (CIPN-P) has not been fully validated, and which drugs are associated with a decreased incidence of neuropathy in this context remains unclear.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study by using the nationwide Medical Data Vision claims database in Japan, which includes patients treated at acute-care hospitals. From April 2008 to December 2022, 119,061 patients with T2D were prescribed hypoglycemic agents and received platinum-based chemotherapy. Patients with type 1 diabetes, other diabetes types, or pre-existing neuropathy were excluded. The outcome, CIPN-P, was defined as a new prescription of gabapentin, duloxetine, mirogabalin, pregabalin, or cyanocobalamin following an International Classification of Diseases, 10th Revision code for peripheral neuropathy. Patients were followed for 3 years after chemotherapy. Baseline covariates included age, sex, body mass index, hemoglobin A1c, and estimated glomerular filtration rate. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). We examined their diagnoses, treatments, and procedures, categorizing them into patients with CIPN-P (n = 22,559) and those without (n = 96,502).</p><p><strong>Results: </strong>The incidence of CIPN-P was 18.9%. The concomitant use of sodium-glucose cotransporter 2 inhibitors was associated with a lower risk of CIPN-P, with an overall HR of 0.89 (95% CI: 0.82-0.96, p = 0.01). Empagliflozin (HR: 0.85) and dapagliflozin (HR: 0.85) were each associated with a significantly lower risk.</p><p><strong>Conclusion: </strong>These results suggest that sodium-glucose cotransporter 2 inhibitors may be associated with a lower risk of CIPN-P in patients undergoing platinum-based chemotherapy. These associations may support more individualized antidiabetic treatment strategies in patients receiving platinum-based chemotherapy.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1033-1043"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147691275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/ocl/aebag004","DOIUrl":"10.1159/ocl/aebag004","url":null,"abstract":"<p><p>This is a correction to: Junjie Huang, Claire Chenwen Zhong, Zhaojun Li, Yu Jiang, Zehuan Yang, Jinqiu Yuan, Jonathan Poon, Qi Dou, Martin C.S. Wong; Machine Learning Predictive Models for Survival in Gastric Cancer Patients with Diabetes: A Population-Based Cohort Study. Oncology. 2026;104(6):713-732. https://doi.org/10.1159/000548220.Following publication, the authors requested to correct the Statement of Ethics in the article.Incorrect statement: \"The Survey and Behavioural Research Ethics Committee of the Chinese University of Hong Kong approved the study (Approval No. SBRE-22-0303A). The need for written informed consent was waived by the relevant Ethics Committee or Institutional Review Board.\"Corrected statement: \"The Survey and Behavioural Research Ethics Committee of the Chinese University of Hong Kong approved the study (Approval No. SBRE-22-0303A), and the Joint Chinese University of Hong Kong (CUHK) and New Territories East Cluster (NTEC) Clinical Research Ethics Committee (CREC) (Application No. NTEC-2024-446; Reference No. 2024.423). The need for written informed consent was waived by the relevant Ethics Committee or Institutional Review Board.\"The authors state that this correction does not alter the scientific results, analysis, or conclusions of the original article. The original article has been linked accordingly.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1243-1244"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13561503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decision-Making in Intrathecal Therapy for Leptomeningeal Disease.","authors":"Susanne Weindler, Thomas Hundsberger, Alfredo Addeo, Patrizia Froesch, Martin Früh, Oliver Gautschi, Ursula Hasler-Strub, Wolf-Dieter Janthur, Joanna Mangana, Cristina Mangas, Michael Thomas Mark, Julia-Tatjana Maul, Lara Valeska Maul, Laetitia Arja Mauti, Yannis Metaxas, Tilly Nothhelfer, Berna C Özdemir, Emilie Le Rhun, Sacha I Rothschild, Sabine Schmid, Katharina Seystahl, Philippe Schucht, Marcus Vetter, Michael Weller, Isabell Witzel, Khalil Zaman, Paul Martin Putora, Markus Glatzer","doi":"10.1159/000552332","DOIUrl":"10.1159/000552332","url":null,"abstract":"<p><strong>Introduction: </strong>Guidelines suggest intrathecal (IT) pharmacotherapy for patients with leptomeningeal disease (LMD). However, evidence on the benefit of IT treatment is limited and IT therapy is an invasive procedure in patients with limited life expectancy. Available drugs for IT therapy do not play a role in systemic treatment of the most common cancers related to LMD, and it is unclear to which extent and how the recommendation for IT therapy is implemented in daily clinical practice.</p><p><strong>Methods: </strong>A panel of 24 dedicated Swiss experts in the field of breast cancer, lung cancer, melanoma, and neuro-oncology recommended by the disease group leaders of the Swiss Cancer Institute (formerly SAKK) provided their decision criteria for the use of IT treatment in LMD. Treatment strategies were converted into decision trees and evaluated for consensus and discrepancies based on the objective consensus methodology.</p><p><strong>Results: </strong>We identified 11 criteria relevant for decision-making in IT therapy for LMD. The criteria most often used in the decision-making process were confirmed LMD (positive cerebrospinal fluid), performance status, availability of systemic drugs with CNS efficacy, and extracranial disease control. Only half of all participating experts recommend IT therapy in their daily practice. Swiss experts from the field of neuro-oncology most often recommended IT treatment whereas lung cancer experts were most reluctant.</p><p><strong>Conclusion: </strong>Implementation of IT pharmacotherapy in daily clinical practice varies widely both between individual experts and between experts' specialization in different cancers. Only half of the participating experts would recommend IT therapy to their patients. In everyday clinical practice, treatment recommendations are highly individualized and optimal care for LMD can only be achieved involving a truly multidisciplinary team of specialists.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1203-1214"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147988571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Real-World Pharmacovigilance Analysis of HER2 Inhibitor-Induced Cardiovascular Toxicity.","authors":"Jianhui Yao, Chao Tao, Weiyi Chen, Ruixiao Li, Ke Wang, Jinlu Shang, Meiling Zhou","doi":"10.1159/000553521","DOIUrl":"10.1159/000553521","url":null,"abstract":"<p><strong>Introduction: </strong>With the widespread use of human epidermal growth factor receptor 2 (HER2) inhibitors in cancer treatment, cardiovascular diseases induced by these agents have become a significant adverse event.</p><p><strong>Methods: </strong>We retrieved reports of HER2 inhibitor-induced cardiovascular adverse events (CVAEs) from the FDA Adverse Event Reporting System(FAERS) database, covering the period from the first quarter of 2004 to the fourth quarter of 2024. Disproportionality analyses were conducted using reporting odds ratios and proportional reporting ratios. The signals of HER2 inhibitor-related CVAEs were evaluated at both the standardized MedDRA query and preferred term levels.</p><p><strong>Results: </strong>A total of 12,698 reports associated with CVAEs were identified, with HER2 inhibitors listed as the primary suspected drug, involving 12,398 patients. Most cases were observed in individuals aged 45 years and older, with a notably higher proportion in women. The time to onset of HER2 inhibitor-induced CVAEs showed certain variability. Trastuzumab exhibited higher cardiovascular toxicity compared with other HER2 inhibitors. In general, monoclonal antibodies demonstrated greater cardiovascular toxicity, whereas antibody-drug conjugates and HER2-tyrosine kinase inhibitors displayed comparable and lower effects.</p><p><strong>Conclusion: </strong>This pharmacovigilance analysis reveals a strong association between HER2 inhibitors and CVAEs, providing valuable insights for their prevention and clinical management.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1189-1202"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148549957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}